Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers : A Primer on Commonly Used Cancer Markers
Copyright 2023, Desai et al..
Cancer markers are molecules produced by cancer cells which may serve to identify the presence of cancer. Cancer markers can be differentiated as serum-based, radiology-based and tissue-based, and are one of the most important tools in diagnosing, staging and monitoring of treatment of many cancers. The most used cancer markers are serum cancer markers due to its relative ease and lower cost of testing. However, serum cancer markers have poor mass screening utilization due to poor positive predictive value. Several markers such as prostate-specific antigen (PSA), beta-human chorionic gonadotropin (B-hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) are used to aid in diagnosis of cancer in cases of high suspicion. Serum markers such as carcinoembryonic antigen (CEA), AFP, carbohydrate antigen 19-9 (CA 19-9), and 5-hydroxyindoleacetic acid (5-HIAA) play a significant role in assessing disease prognosis as well as response to treatment. This work reviews the role of some of the biomarkers in the diagnosis and treatment of cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
World journal of oncology - 14(2023), 1 vom: 14. Feb., Seite 4-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Desai, Shreya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5-HIAA |
|---|
| Anmerkungen: |
Date Revised 11.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14740/wjon1425 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354016873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354016873 | ||
| 003 | DE-627 | ||
| 005 | 20231226061320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14740/wjon1425 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354016873 | ||
| 035 | |a (NLM)36895994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Desai, Shreya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers |b A Primer on Commonly Used Cancer Markers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright 2023, Desai et al. | ||
| 520 | |a Cancer markers are molecules produced by cancer cells which may serve to identify the presence of cancer. Cancer markers can be differentiated as serum-based, radiology-based and tissue-based, and are one of the most important tools in diagnosing, staging and monitoring of treatment of many cancers. The most used cancer markers are serum cancer markers due to its relative ease and lower cost of testing. However, serum cancer markers have poor mass screening utilization due to poor positive predictive value. Several markers such as prostate-specific antigen (PSA), beta-human chorionic gonadotropin (B-hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) are used to aid in diagnosis of cancer in cases of high suspicion. Serum markers such as carcinoembryonic antigen (CEA), AFP, carbohydrate antigen 19-9 (CA 19-9), and 5-hydroxyindoleacetic acid (5-HIAA) play a significant role in assessing disease prognosis as well as response to treatment. This work reviews the role of some of the biomarkers in the diagnosis and treatment of cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 5-HIAA | |
| 650 | 4 | |a AFP | |
| 650 | 4 | |a B-hCG | |
| 650 | 4 | |a CA 19-9 | |
| 650 | 4 | |a CA 27-29 | |
| 650 | 4 | |a CA-125 | |
| 650 | 4 | |a CEA | |
| 650 | 4 | |a Calcitonin | |
| 650 | 4 | |a Cancer screening | |
| 650 | 4 | |a LDH | |
| 650 | 4 | |a PSA | |
| 650 | 4 | |a Prognostic markers | |
| 650 | 4 | |a Serum markers | |
| 650 | 4 | |a Tumor markers | |
| 700 | 1 | |a Guddati, Achuta K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of oncology |d 2010 |g 14(2023), 1 vom: 14. Feb., Seite 4-14 |w (DE-627)NLM210566469 |x 1920-454X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:14 |g month:02 |g pages:4-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14740/wjon1425 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 14 |c 02 |h 4-14 | ||